-
1
-
-
57649202651
-
Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic
-
Citrome L. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Int. J. Clin. Pract. 2009, 63(1):140-150.
-
(2009)
Int. J. Clin. Pract.
, vol.63
, Issue.1
, pp. 140-150
-
-
Citrome, L.1
-
2
-
-
67749095284
-
Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic
-
Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. Int. J. Clin. Pract. 2009, 63(8):1237-1248.
-
(2009)
Int. J. Clin. Pract.
, vol.63
, Issue.8
, pp. 1237-1248
-
-
Citrome, L.1
-
3
-
-
72449129531
-
Paliperidone palmitate-review of the efficacy, safety, and cost of a new second-generation depot antipsychotic medication
-
Citrome L. Paliperidone palmitate-review of the efficacy, safety, and cost of a new second-generation depot antipsychotic medication. Int. J. Clin. Pract. 2010, 64(2):216-239.
-
(2010)
Int. J. Clin. Pract.
, vol.64
, Issue.2
, pp. 216-239
-
-
Citrome, L.1
-
4
-
-
0029910610
-
Utilization of depot neuroleptic medication in psychiatric inpatients
-
Citrome L., Levine J., Allingham B. Utilization of depot neuroleptic medication in psychiatric inpatients. Psychopharmacol. Bull. 1996, 32(3):321-326.
-
(1996)
Psychopharmacol. Bull.
, vol.32
, Issue.3
, pp. 321-326
-
-
Citrome, L.1
Levine, J.2
Allingham, B.3
-
5
-
-
0031705379
-
Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health
-
Citrome L., Levine J., Allingham B. Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health. Psychiatr. Q. 1998, 69(4):283-300.
-
(1998)
Psychiatr. Q.
, vol.69
, Issue.4
, pp. 283-300
-
-
Citrome, L.1
Levine, J.2
Allingham, B.3
-
6
-
-
0034100648
-
Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998
-
Citrome L., Levine J., Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr. Serv. 2000, 51(5):634-638.
-
(2000)
Psychiatr. Serv.
, vol.51
, Issue.5
, pp. 634-638
-
-
Citrome, L.1
Levine, J.2
Allingham, B.3
-
7
-
-
0036787358
-
Use of mood stabilizers among patients with schizophrenia, 1994-2001
-
Citrome L., Jaffe A., Levine J., Allingham B. Use of mood stabilizers among patients with schizophrenia, 1994-2001. Psychiatr. Serv. 2002, 53(10):1212.
-
(2002)
Psychiatr. Serv.
, vol.53
, Issue.10
, pp. 1212
-
-
Citrome, L.1
Jaffe, A.2
Levine, J.3
Allingham, B.4
-
8
-
-
4444286682
-
Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients
-
Citrome L., Jaffe A., Levine J., Allingham B., Robinson J. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr. Serv. 2004, 55(9):1006-1013.
-
(2004)
Psychiatr. Serv.
, vol.55
, Issue.9
, pp. 1006-1013
-
-
Citrome, L.1
Jaffe, A.2
Levine, J.3
Allingham, B.4
Robinson, J.5
-
9
-
-
23044440036
-
Dosing of second-generation antipsychotic medication in a state hospital system
-
Citrome L., Jaffe A., Levine J. Dosing of second-generation antipsychotic medication in a state hospital system. J. Clin. Psychopharmacol. 2005, 25(4):388-391.
-
(2005)
J. Clin. Psychopharmacol.
, vol.25
, Issue.4
, pp. 388-391
-
-
Citrome, L.1
Jaffe, A.2
Levine, J.3
-
10
-
-
30344469722
-
Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies
-
Citrome L., Jaffe A., Levine J., Lindenmayer J.P. Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. J. Clin. Psychiatry 2005, 66(12):1512-1516.
-
(2005)
J. Clin. Psychiatry
, vol.66
, Issue.12
, pp. 1512-1516
-
-
Citrome, L.1
Jaffe, A.2
Levine, J.3
Lindenmayer, J.P.4
-
11
-
-
33747024519
-
Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997-2004
-
Citrome L., Jaffe A., Levine J., Martello D. Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997-2004. Psychiatr. Serv. 2006, 57(8):1132-1139.
-
(2006)
Psychiatr. Serv.
, vol.57
, Issue.8
, pp. 1132-1139
-
-
Citrome, L.1
Jaffe, A.2
Levine, J.3
Martello, D.4
-
12
-
-
33847045551
-
Datapoints: the ups and downs of dosing second-generation antipsychotics
-
Citrome L., Jaffe A., Levine J. Datapoints: the ups and downs of dosing second-generation antipsychotics. Psychiatr. Serv. 2007, 58(1):11.
-
(2007)
Psychiatr. Serv.
, vol.58
, Issue.1
, pp. 11
-
-
Citrome, L.1
Jaffe, A.2
Levine, J.3
-
13
-
-
68049131363
-
How dosing of ziprasidone in a state hospital system differs from product labeling
-
Citrome L., Jaffe A., Levine J. How dosing of ziprasidone in a state hospital system differs from product labeling. J. Clin. Psychiatry 2009, 70(7):975-982.
-
(2009)
J. Clin. Psychiatry
, vol.70
, Issue.7
, pp. 975-982
-
-
Citrome, L.1
Jaffe, A.2
Levine, J.3
-
14
-
-
74849092225
-
Datapoints: depot antipsychotic use in New York State hospitals, 1994 to 2009
-
Citrome L., Jaffe A., Levine J. Datapoints: depot antipsychotic use in New York State hospitals, 1994 to 2009. Psychiatr. Serv. 2010, 61(1):9.
-
(2010)
Psychiatr. Serv.
, vol.61
, Issue.1
, pp. 9
-
-
Citrome, L.1
Jaffe, A.2
Levine, J.3
-
15
-
-
12844251255
-
Long-acting injectable risperidone
-
Ehret M.J., Fuller M.A. Long-acting injectable risperidone. Ann. Pharmacother. 2004, 38(12):2122-2127.
-
(2004)
Ann. Pharmacother.
, vol.38
, Issue.12
, pp. 2122-2127
-
-
Ehret, M.J.1
Fuller, M.A.2
-
16
-
-
1442348069
-
Long-acting risperidone: a review of its use in schizophrenia
-
Harrison T.S., Goa K.L. Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs 2004, 18(2):113-132.
-
(2004)
CNS Drugs
, vol.18
, Issue.2
, pp. 113-132
-
-
Harrison, T.S.1
Goa, K.L.2
-
17
-
-
0037278766
-
Antipsychotic medication coprescribing in a large state hospital system
-
Jaffe A.B., Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol. Drug Saf. 2003, 12(1):41-48.
-
(2003)
Pharmacoepidemiol. Drug Saf.
, vol.12
, Issue.1
, pp. 41-48
-
-
Jaffe, A.B.1
Levine, J.2
-
18
-
-
0346120179
-
Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia
-
Jaffe A.B., Levine J. Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia. J. Clin. Psychiatry 2003, 64(Suppl 17):3-6.
-
(2003)
J. Clin. Psychiatry
, vol.64
, Issue.SUPPL. 17
, pp. 3-6
-
-
Jaffe, A.B.1
Levine, J.2
-
19
-
-
0036076837
-
A naturalistic study of risperidone treatment outcome using prognosis-adjusted discharge rates in New York State inpatients
-
Javitt D.C., Cienfuegos A., Miniati M., et al. A naturalistic study of risperidone treatment outcome using prognosis-adjusted discharge rates in New York State inpatients. J. Clin. Psychiatry 2002, 63(7):585-590.
-
(2002)
J. Clin. Psychiatry
, vol.63
, Issue.7
, pp. 585-590
-
-
Javitt, D.C.1
Cienfuegos, A.2
Miniati, M.3
-
20
-
-
77952671728
-
-
Johnson and Johnson. FDA Approves Invega Sustenna for the Acute and Maintenance Treatment of Schizophrenia. Press release, 31 July 2009. Available at: Accessed 2 September 2009.
-
Johnson and Johnson, 2009. FDA Approves Invega Sustenna for the Acute and Maintenance Treatment of Schizophrenia. Press release, 31 July 2009. Available at: Accessed 2 September 2009. http://www.jnj.com/connect/news/all/20090731_153000.
-
(2009)
-
-
-
21
-
-
4444296161
-
Antipsychotic Medication Utilization in a State Mental Hospital System, 1994-2000, Chap. 15
-
Substance Abuse and Mental Health Services Administration, Rockville, MD, R.W. Manderscheid, M.J. Henderson (Eds.) Mental Health United States 2002
-
Levine J., Jaffe A.B. Antipsychotic Medication Utilization in a State Mental Hospital System, 1994-2000, Chap. 15. DHHS Pub Number (SMA) 3938 2004, 199-208. Substance Abuse and Mental Health Services Administration, Rockville, MD. R.W. Manderscheid, M.J. Henderson (Eds.).
-
(2004)
DHHS Pub Number (SMA) 3938
, pp. 199-208
-
-
Levine, J.1
Jaffe, A.B.2
-
22
-
-
0018775268
-
The role of depot neuroleptics in the treatment of schizophrenic patients
-
Levine J., Schooler N.R., Cassano G.B. The role of depot neuroleptics in the treatment of schizophrenic patients. Psychol. Med. 1979, 9(2):383-386.
-
(1979)
Psychol. Med.
, vol.9
, Issue.2
, pp. 383-386
-
-
Levine, J.1
Schooler, N.R.2
Cassano, G.B.3
-
23
-
-
71449109074
-
Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia
-
Mohamed S., Rosenheck R., Harpaz-Rotem I., Leslie D., Sernyak M.J. Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia. Psychiatr. Q. 2009, 80(4):241-249.
-
(2009)
Psychiatr. Q.
, vol.80
, Issue.4
, pp. 241-249
-
-
Mohamed, S.1
Rosenheck, R.2
Harpaz-Rotem, I.3
Leslie, D.4
Sernyak, M.J.5
-
24
-
-
34250005736
-
Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care
-
Niaz O.S., Haddad P.M. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr. Scand. 2007, 116(1):36-46.
-
(2007)
Acta Psychiatr. Scand.
, vol.116
, Issue.1
, pp. 36-46
-
-
Niaz, O.S.1
Haddad, P.M.2
-
25
-
-
77952668428
-
-
Otsuka Pharmaceutical Development & Commercialization, Inc., 2008. Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients with Schizophrenia (ASPIRE). Registry entry, 7 Aug 2008. Available at: Accessed 31 Oct.
-
Otsuka Pharmaceutical Development & Commercialization, Inc., 2008. Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients with Schizophrenia (ASPIRE). Registry entry, 7 Aug 2008. Available at: Accessed 31 Oct 2008. http://clinicaltrials.gov/ct2/show/NCT00731549.
-
(2008)
-
-
-
26
-
-
76949089882
-
Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries
-
Peuskens J., Olivares J.M., Pecenak J., et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr. Med. Res. Opin. 2010, 26(3):501-509.
-
(2010)
Curr. Med. Res. Opin.
, vol.26
, Issue.3
, pp. 501-509
-
-
Peuskens, J.1
Olivares, J.M.2
Pecenak, J.3
-
27
-
-
77952673745
-
Risperidone long-acting injection: factors associated with changes in bed stay and hospitalisation in a 3-year naturalistic follow-up
-
Mar 12 [Electronic publication]
-
Taylor D., Cornelius V. Risperidone long-acting injection: factors associated with changes in bed stay and hospitalisation in a 3-year naturalistic follow-up. J. Psychopharmacol. 2009, Mar 12 [Electronic publication].
-
(2009)
J. Psychopharmacol.
-
-
Taylor, D.1
Cornelius, V.2
-
28
-
-
33846284148
-
Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome
-
Taylor D.M., Young C., Patel M.X. Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome. Int. J. Neuropsychopharmacol. 2006, 9(6):685-694.
-
(2006)
Int. J. Neuropsychopharmacol.
, vol.9
, Issue.6
, pp. 685-694
-
-
Taylor, D.M.1
Young, C.2
Patel, M.X.3
-
29
-
-
67649939217
-
Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use
-
Taylor D., Fischetti C., Sparshatt A., Thomas A., Bishara D., Cornelius V. Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use. Acta Psychiatr. Scand. 2009, 120(2):97-101.
-
(2009)
Acta Psychiatr. Scand.
, vol.120
, Issue.2
, pp. 97-101
-
-
Taylor, D.1
Fischetti, C.2
Sparshatt, A.3
Thomas, A.4
Bishara, D.5
Cornelius, V.6
-
30
-
-
62649096283
-
Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice
-
Taylor D., Fischetti C., Sparshatt A., Thomas A., Bishara D., Cornelius V. Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice. J. Clin. Psychiatry 2009, 70(2):196-200.
-
(2009)
J. Clin. Psychiatry
, vol.70
, Issue.2
, pp. 196-200
-
-
Taylor, D.1
Fischetti, C.2
Sparshatt, A.3
Thomas, A.4
Bishara, D.5
Cornelius, V.6
-
31
-
-
0029128286
-
Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen
-
Weiden P., Rapkin B., Zygmunt A., et al. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr. Serv. 1995, 46(10):1049-1054.
-
(1995)
Psychiatr. Serv.
, vol.46
, Issue.10
, pp. 1049-1054
-
-
Weiden, P.1
Rapkin, B.2
Zygmunt, A.3
-
32
-
-
33745092184
-
Health resource utilization associated with switching to risperidone long-acting injection
-
Young C.L., Taylor D.M. Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr. Scand. 2006, 114(1):14-20.
-
(2006)
Acta Psychiatr. Scand.
, vol.114
, Issue.1
, pp. 14-20
-
-
Young, C.L.1
Taylor, D.M.2
|